tbuckley/cabot-search huggingface dataset:
Abstract 17236: Intracranial Hemorrhage in Patients With Atrial Fibrillation in the ARISTOTLE Trial: Clinical Characteristics and Associated Outcomes
Authors: Renato D Lopes, Bradley J Kolls, Patricia O Guimaraes, Daniel M Wojdyla, Michael Hanna, J. Donald Easton, Laine Thomas, Lars Wallentin, Sana M Al-Khatib, Claes Held, John H Alexander, Christopher B Granger, Hans-Christoph Diener
Journal: Circulation (2015)

Background: Intracranial hemorrhage (ICH) is associated with poor outcomes in patients with atrial fibrillation (AF) treated with oral anticoagulation. Little is known about clinical characteristics and factors associated with ICH and subsequent outcomes in patients receiving apixaban. Methods: The ARISTOTLE trial randomized 18,201 patients with AF and risk of stroke to warfarin or apixaban. All ICH events were identified and adjudicated by a central committee blinded to the study treatment assignment. ICH events were analyzed in patients receiving at least one dose of study drug (N=18,140). Multivariable cox regression models were developed to identify factors associated with ICH. Results: There were 174 (1.0%) ICH events. Of those, 111 (67.7%) were intracerebral hemorrhage, 50 (30.7%) subdural hematomas, and 25 (15.3%) subarachnoid hemorrhage. Patients with ICH were older and had higher CHADS 2 score than patients without ICH. Computed tomography was used in 95.2% of patients for the diagnosis of ICH. The majority of ICH cases were spontaneous (71.7%) and 91.4% of patients with ICH presented with some type of neurological deficit. Most (72%) of the patients received conservative treatment and 21% underwent surgical intervention; 71 (40.8%) patients died in hospital. The mean modified Rankin score at discharge of survivors was ≥4 in 23 (22%) patients. Apixaban was superior to warfarin in causing less ICH, including as categorized by each ICH location. Factors associated with ICH were older age, warfarin randomized treatment assignment, prior stroke, geographic region of the world, and use of aspirin at randomization (Table). Conclusion: ICH is uncommon in patients with AF who are treated with oral anticoagulant and is associated with very high mortality. Apixaban is superior to warfarin in causing less ICH, irrespective of the location and other risk factors for ICH.
Minimally Invasive versus Abdominal Radical Hysterectomy for Cervical Cancer
Authors: Pedro T. Ramirez, Michael Frumovitz, Rene Pareja, Aldo Lopez, Marcelo Vieira, Reitan Ribeiro, Alessandro Buda, Xiaojian Yan, Yao Shuzhong, Naven Chetty, David Isla, Mariano Tamura, Tao Zhu, Kristy P. Robledo, Val Gebski, Rebecca Asher, Vanessa Behan, James L. Nicklin, Robert L. Coleman, Andreas Obermair
Journal: New England Journal of Medicine (2018)

There are limited data from retrospective studies regarding whether survival outcomes after laparoscopic or robot-assisted radical hysterectomy (minimally invasive surgery) are equivalent to those after open abdominal radical hysterectomy (open surgery) among women with early-stage cervical cancer.
Judge rules that man at risk of septic shock within weeks should have colostomy
Authors: Clare Dyer
Journal: BMJ (2018)

A High Court judge has given the go ahead for a 43 year old doubly incontinent man to have a colostomy, after hearing that doctors feared that he would die from septic shock within four to six weeks unless the procedure was performed.

The ruling was made in August in the Court of Protection but has just been published.

Mr Justice Moor ruled that it would be “overwhelmingly” in the interests of the man, referred to as SJ, to have the operation. SJ has a history of psychotic episodes, and it was thought that he might have an autism spectrum disorder. The judge made a finding that SJ …
A deep learning approach to automate refinement of somatic variant calling from cancer sequencing data
Authors: Benjamin J. Ainscough, Erica K. Barnell, Peter Ronning, Katie M. Campbell, Alex H. Wagner, Todd A. Fehniger, Gavin P. Dunn, Ravindra Uppaluri, Ramaswamy Govindan, Thomas E. Rohan, Malachi Griffith, Elaine R. Mardis, S. Joshua Swamidass, Obi L. Griffith
Journal: Nature Genetics (2018)
Current developments in drug delivery with thermosensitive liposomes
Authors: Hongshu Bi, Jianxiu Xue, Hong Jiang, Shan Gao, Dongjuan Yang, Yan Fang, Kai Shi
Journal: Asian Journal of Pharmaceutical Sciences (2018)

Thermosensitive liposomes (TSLs) have been an important research area in the field of tumor targeted chemotherapy. Since the first TSLs appeared that using 1,2-dipalmitoyl-sn-glyce-ro-3-phosphocholine (DPPC) as the primary liposomal lipid, many studies have been done using this type of liposome from basic and practical aspects. While TSLs composed of DPPC enhance the cargo release near the phase transition temperature, it has been shown that many factors affect their temperature sensitivity. Thus numerous attempts have been undertaken to develop new TSLs for improving their thermal response performance. The main objective of this review is to introduce the development and recent update of innovative TSLs formulations, including combination of radiofrequency ablation (RFA), high-intensity focused ultrasound (HIFU), magnetic resonance imaging (MRI) and alternating magnetic field (AMF). In addition, various factors affecting the design of TSLs, such as lipid composition, surfactant, size and serum components are also discussed.
Continuing Problems With Financial Conflicts of Interest and Clinical Practice Guidelines
Authors: Colette DeJong, Robert Steinbrook
Journal: JAMA Internal Medicine (2018)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal
Healthy Behavior, Risk Factor Control, and Survival in the COURAGE Trial
Authors: David J. Maron, G.B. John Mancini, Pamela M. Hartigan, John A. Spertus, Steven P. Sedlis, William J. Kostuk, Daniel S. Berman, Koon K. Teo, William S. Weintraub, William E. Boden
Journal: Journal of the American College of Cardiology (2018)
The T Cell Antigen Receptor α Transmembrane Domain Coordinates Triggering through Regulation of Bilayer Immersion and CD3 Subunit Associations
Authors: Kristine N. Brazin, Robert J. Mallis, Andras Boeszoermenyi, Yinnian Feng, Akihiro Yoshizawa, Pedro A. Reche, Pavanjeet Kaur, Kevin Bi, Rebecca E. Hussey, Jonathan S. Duke-Cohan, Likai Song, Gerhard Wagner, Haribabu Arthanari, Matthew J. Lang, Ellis L. Reinherz
Journal: Immunity (2018)
Barriers and Facilitators to Mediterranean Diet Adoption by Patients With Nonalcoholic Fatty Liver Disease in Northern Europe
Authors: Laura Haigh, Susan Bremner, David Houghton, Elsbeth Henderson, Leah Avery, Timothy Hardy, Kate Hallsworth, Stuart McPherson, Quentin M. Anstee
Journal: Clinical Gastroenterology and Hepatology (2018)
Assessment of Reported Trial Characteristics, Rate of Publication, and Inclusion of Mandatory Biopsies of Research Biopsies in Clinical Trials in Oncology
Authors: Christine M. Parseghian, Alda L. Tam, James Yao, Joe Ensor, Lee M. Ellis, Kanwal Raghav, Michael J. Overman
Journal: JAMA Oncology (2018)

Research biopsies are frequently incorporated within clinical trials in oncology and are often a mandatory requirement for trial enrollment. However, limited information is available regarding the extent and completeness of research biopsy reporting.To determine the rate of research biopsy reporting for clinical trials registered in ClinicalTrials.gov and determine the clinical trial factors that correlated with research biopsy reporting.ClinicalTrials.gov (CTG) was searched for all oncologic therapeutic clinical trials with completion dates between January 1, 2000, and January 1, 2015, with end point category terms including biopsy, biopsies, or tissue. The date of the final publication search was March 12, 2018. Trials conducting only diagnostic biopsies or trials using bone marrow biopsies or liquid biopsies were excluded. Credit for biopsy reporting was given for any mention of performing or results from tissue biopsies in publications. Clinical trials were compared with the highest level of corresponding publication or registry report. Fisher exact test was used for analysis.A total of 301 clinical trials were identified, with a median of 37 patients (range, 1-1310 patients) enrolled per trial. After a median follow-up time of 5.8 years from trial completion, 244 of 301 trials (81.1%) reported results: publications in 195 (64.8%) and CTG registry in 49 (16.3%). Reporting of trial results was associated with later-stage trials (phase 2/3) (137 of 153 [89.5%] for phase 2/3 vs 107 of 148 [72.3%] for phase 1 or 1/2 trials; P < .001). Results from research biopsies were reported in 153 of 301 (50.8%) trials or in 153 of 244 (62.7%) trials with published results. Rates varied by type of presentation: 142 of 195 publications (72.8%) vs 11 of 49 CTG reports (22.4%) (P < .001). Conducting mandatory biopsies (82.1% [101 of 123] vs 43.0% [52 of 121]; P < .001), early-phase clinical trials (70.1% [75 of 107] vs 56.9% [78 of 137]; P = .03), and listing the biopsy as a primary objective in CTG (76.3% [45 of 59] vs 58.4% [108 of 185]; P = .01) was associated with improved biopsy reporting. Trials that met their primary end point (71.9% [115 of 160] vs 45.2% [38 of 84]; P < .001) and those published in higher-impact journals (81.1% [77 of 95] vs 65.0% [65 of 100]; P = .01) had improved biopsy reporting. Mandatory biopsies and biopsy reporting increased over time with similar slopes (P = .58).Despite ethical obligations to report research biopsies, only 50.8% of all trials that included a research biopsy-related end point in CTG reported on these biopsy-related results. Improved efforts are needed to report results obtained from research biopsies.
Abstract 343: Embryonic Extracellular Matrix and Cardiomyocyte Maturation
Authors: Stefan M Kren, Daniel J Garry, Mary G Garry
Journal: Circulation Research (2017)

Background: The progression of cell maturation is governed by intrinsic factors, but also by interaction with the milieu in which they reside. The extracellular matrix (ECM) from rapidly developing tissue should form a rich signaling environment for cellular development. Hypothesis: Murine embryonic ECM can be prepared by detergent decellularization that is morphologically preserved, biocompatible for cell culture, and at E13.5, substantial enough to permit vascular catheterization and recellularization by perfusion. When used as a scaffold for cell culture, it can be shown to have a salutatory effect on the morphologic and physiologic maturation of post-natal cardiomyocytes (CM). Methods and Results: To test the contribution of embryonic ECM to the performance of cardiomyocytes in culture, we undertook the isolation of ECM from developing murine embryos. Using a detergent decellularization protocol, we established an acellular scaffold that was shown to be free of native cells and returned to a biocompatible state, to serve as a scaffold for cell culture. Primary P7 mCherry expressing cardiomyocytes were isolated and introduced by perfusion into the embryonic ECM heart. The same cells were also plated, and the performance of the two culture modalities was compared at 3 and 28 days. Histologic comparison demonstrated the maintenance of the rod cellular morphology. Analysis of cellular contractile performance by video microscopy demonstrated improved contractile performance of CMs when cultured on ECM and paced at 1 Hz (3 Day plated contraction velocity/relaxation velocity (μm/sec) 1.18±0.3/0.91±0.2 and ECM contraction velocity/relaxation velocity (μm/sec) 6.65±1.0/4.52±0.7). At 28 days plated contraction velocity/relaxation velocity was (μm/sec) 2.71±0.2/1.59±0.1 and ECM contraction velocity/relaxation velocity was (μm/sec) 8.83±4.2/6.20±2.6). Conclusion: Biocompatible, acellular morphologically preserved embryonic ECM can be extracted from E13.5 murine embryos. By E13.5 the structural integrity of the acellular matrix can sustain vascular perfusion for delivery of P7 cardiomyocytes to internal organoid structures. These ECM preparations support the maturation and physiologic performance of cardiomyocytes.
Socioeconomic deprivation and inequalities in lung cancer: time to delve deeper?
Authors: Helen A Powell
Journal: Thorax (2018)

Inequalities in lung cancer care between the richest and poorest in society attract attention and rightly so; the disease is most prevalent and survival poorest in those who are deprived.1 Through improved awareness, earlier diagnosis and higher rates of curative treatment, predominantly by surgical resection, we have seen improvements in lung cancer survival over the last decade. Unfortunately, there is evidence to suggest that deprived people are less likely to benefit from any of these interventions compared with the more affluent. Socioeconomic deprivation is associated with reduced participation in lung cancer screening trials.2 This is due, at least in part, to perceptions that lung cancer is an uncontrollable, self-inflicted, smokers’ disease.3 Encouraging results from a study of ‘Lung Health Checks’ in Manchester suggest that it is possible to reach more deprived people if the service is designed appropriately.4 

Survival differences between the most and least deprived patients with lung cancer may be related to comorbidity; it is well recognised that overall survival from cancer is worse in poorer people.5 In lung cancer specifically, this may reflect differences in treatment rates and, even without the specific effects of socioeconomic variation, there are geographical variations in lung cancer treatment rates, attributed by some to varying practice between multidisciplinary teams (MDT).6 In this issue of Thorax , Belot et al 7 add to the growing body of evidence that the higher …
Abstract 20456: The Estimated Effects of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers in a High-Risk Cardiac Population
Authors: Linnea A Polgreen, Benjamin N Riedle, Barry L Carter, Philip M Polgreen
Journal: Circulation (2017)

Introduction: Randomized controlled trials determine causative effects but may not be generalizable to older patients and patients with comorbidities. Using a cohort of Medicare beneficiaries who e...
SAT0267 Efficacy and safety of bcd-055, proposed infliximab biosimilar, compared to infliximab: 54-week results from asart-2 phase 3 clinical study
Authors: L. Denisov, P. Shesternya, T. Plaksina, T. Kropotina, N. Soroka, E. Kunder, A. Lutskii, A. Eremeeva, E. Dokukina, E. Chernyaeva, R. Ivanov, V. Mazurov
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> Non-inferiority of BCD-055 in direct comparison to infliximab originator after 30 weeks of treatment in patients with ankylosing spondylitis (AS) was shown previously<sup>1</sup>. Here we present 54 week safety and efficacy data in ITT population from international double-blind randomised ASART-2 clinical trial. <h3>Objectives</h3> To compare BCD-055, proposed infliximab biosimilar and infliximab originator in terms of efficacy and safety in patients with AS. <h3>Methods</h3> Adult patients (n=199) aged 18–65 years, with active AS (BASDAI&gt;4) received 5 mg/kg of BCD-055 (n=132) or infliximab (n=67) IV on w0, w2 and w6 and then every 8 w until w54. The results of the primary endpoint assessment (ASAS20 at w30) were presented earlier<sup>1</sup>. Secondary endpoints were proportion of patients, achieved ASAS20/40, and mean change from baseline in BASDAI, BASMI, BASFI, MASES, SF36 scores, chest excursion and TJC<sup>44</sup> at w54. Rate of AEs and proportion of patient with ADA to infliximab in both groups were also evaluated. <h3>Results</h3> The proportions of patients achieved ASAS20/ASAS40 were similar in both study groups at w54 (Abstract SAT0267 – figure 1). Improvement in AS symptoms showed similar dynamics in both groups: significant decrease in AS activity (BASDAI) and improvement in other secondary endpoints has developed within the first 14 weeks of treatment in both study groups and remained at achieved level until w54. The magnitude of changes of all evaluated parameters did not differ between groups. No statistically significant differences in rates of AEs were found between study groups (table 1). Most common reported AEs were infections, hematologic and vascular disorders, hypersensitivity reactions. Formation of ADA to infliximab was detected with similar frequency in both groups. <h3>Conclusions</h3> The 54 week results supports previously confirmed similar efficacy and safety of BCD-055, proposed infliximab biosimilar, and infliximab originator in patients with active AS. At all evaluated time points the efficacy as well as rate of AEs/SAEs did not differ between BCD-055 and infliximab originator groups. <h3>Reference</h3> [1] Denisov L, Gordeev I, Mazurov V, et al. FRI0208 Comparison of efficacy, safety and pharmacokinetics of infliximab biosimilar (BCD-055) and innovator infliximabAnn Rheum Dis2017;76:560–561. <h3>Disclosure of Interest</h3> L. Denisov: None declared, P. Shesternya: None declared, T. Plaksina: None declared, T. Kropotina: None declared, N. Soroka: None declared, E. Kunder: None declared, A. Lutskii Employee of: JSC BIOCAD, A. Eremeeva Employee of: JSC BIOCAD, E. Dokukina Employee of: JSC BIOCAD, E. Chernyaeva Employee of: JSC BIOCAD, R. Ivanov Employee of: JSC BIOCAD, V. Mazurov: None declared
Abstract 18158: Neointimal Coverage of Overlapping Everolimus-eluting Bioresorbable Scaffolds: An Optical Coherence Tomography Study in Native Coronary Arteries
Authors: Takao Sato, Mohamed Abdel-Wahab, Mohamed El-Mawardy, Ralph Tölg, Gert Richardt
Journal: Circulation (2015)

Background: Everolimus-eluting bioresorbable scaffolds (BRS) have thick struts, which could influence shear stress and neointimal formation. According to a previous report, the implantation of overlapping BRS has been associated with delayed coverage at 28-days after BRS implantaion. The aim of the present study was to investigate the relationship between BRS overlap and neointimal formation at long-term, using optical coherence tomography (OCT). Method: 32 patients (35 lesions) treated with overlapping BRS underwent follow-up OCT at 11.8±3.0 months after percutaneous coronary intervention. Neointimal area and %uncovered strut were analyzed by OCT at the overlapping BRS site (OBS), non-overlapping proximal and distal BRS sites (NOPBS and NODBS, respectively). Neointimal area was defined as scaffold area - [lumen area + black box (strut)]. %neointimal area was defined as the neointimal areaх100/ scaffold area. In addition, we evaluated the frequency of inter-strut invaginations (hollows) at OBS and non-overlapping sites, which have been suggested as a marker of abnormal vascular reactions to the eluted drug and/or the polymer. Hollows were counted if they exsisted in-between and outside apposed BRS struts. Result: Mean stent diameter and length of overlapped distal BRS and proximal BRS were 2.96±0.39 and 23.1±6.4mm, and 3.11±0.39 and 19.5±6.4mm, respectively. Mean overlap length of BRS was 2.5±1.3mm. At follow-up, %neointimal area was significantly higher at OBS compared to NODBS and NOPBS (35.1±7.8 vs. 20.1±6.2 vs. 21.3±7.6%, respectively, p=0.01). No correlation was observed between the overlap length and %neointimal area. Additionally, %uncovered strut of NODBS and NOPBS was similar to that of OBS. However, the frequency of hollows in OBS was significantly higher than in both NODBS and NOPBS (0.54±0.52 vs. 0.14±0.18 vs. 0.15±0.28/cross-section, respectively, p=0.02). Conclusion: The site of BRS overlap is associated with increased neointimal proliferation one year after implantation, which could be particularly important in patients with small vessels or diffuse coronary disease. Signs of abnormal vascular reactions might be more frequently observed at the site of overlapping BRS compared to non-overlapping site.
Addition of Ixazomib to an Rd Backbone Improves Clinical Benefit in Relapsed/Refractory Multiple Myeloma (RRMM) Patients (Pts) with Non-Canonical NF-KB Activation — Results from the Tourmaline-MM1 Study
Authors: Ajeeta B Dash, Jacob Zhang, Lei Shen, Bin Li, Deborah Berg, Jianchang Lin, Hervé Avet-Loiseau, Nizar Bahlis, Philippe Moreau, Paul Richardson, Alessandra Di Bacco
Journal: Blood (2018)
Positron-Emission Tomography Scan–Directed Chemoradiation for Esophageal Squamous Cell Carcinoma: No Benefit for a Change in Chemotherapy in Positron-Emission Tomography Nonresponders
Authors: Megan Greally, Joanne F. Chou, Daniela Molena, Valerie W. Rusch, Manjit S. Bains, Bernard J. Park, Abraham J. Wu, Karyn A. Goodman, David P. Kelsen, Yelena Y. Janjigian, David H. Ilson, Geoffrey Y. Ku
Journal: Journal of Thoracic Oncology (2018)
Timely Administration of Birth Dose Hepatitis B Virus Vaccine May Break the Chain of Perinatal Transmission
Authors: Aysha Aslam, Rizwan Ishtiaq, Dary T.Y. Lau
Journal: Hepatology (2018)

Aslam, Aysha M.D.; Ishtiaq, Rizwan M.D.; Lau, Dary T.Y. M.D., M.Sc., M.P.H.Editor(s): Corey, Kathleen E.2; Malhi, Harmeet3 Author Information
Outcomes after R-CHOP in patients with newly diagnosed advanced follicular lymphoma: a 10-year follow-up analysis of the JCOG0203 trial
Authors: Takashi Watanabe, Kensei Tobinai, Masashi Wakabayashi, Yasuo Morishima, Hirofumi Kobayashi, Tomohiro Kinoshita, Takayo Suzuki, Motoko Yamaguchi, Kiyoshi Ando, Michinori Ogura, Masafumi Taniwaki, Naokuni Uike, Tadashi Yoshino, Sigeru Nawano, Takashi Terauchi, Tomomitsu Hotta, Hirokazu Nagai, Kunihiro Tsukasaki, Mitsutoshi Kurosawa, Kayo Yamagishi, Naoki Kobayashi, Koichiro Minauchi, Hideo Harigae, Noriko Fukuhara, Naoto Takahashi, Yoshihiro Kameoka, Shin Matsuda, Yurie Saitoh, Norifumi Tsukamoto, Akihiko Yokohama, Nobuko Kubota, Yosuke Minami, Nobuhiko Yamauchi, Kyoya Kumagai, Hideki Tsujimura, Koji Izutsu, Dai Maruyama, Nobuyuki Takayama, Kazuma Ohyashiki, Daigo Akahane, Tatsu Shimoyama, Takaki Shimada, Yutaro Kamiyama, Nobuaki Dobashi, Izumi Wasada, Fumiaki Sano, Madoka Takimoto, Takaaki Chou, Takuro Ishiguro, Yasufumi Masaki, Takahiro Yamauchi, Takaaki Ono, Kazuhito Yamamoto, Harumi Kato, Takashi Tokunaga, Kazuyuki Shimada, Yoko Ushijima, Shinsuke Iida, Shigeru Kusumoto, Toshiki Uchida, Ichiro Hanamura, Jo Kanasugi, Yoshitoyo Kagami, Junji Hiraga, Kana Miyazaki, Takahiko Utsumi, Junya Kuroda, Tsutomu Kobayashi, Itaru Matsumura, Shinya Rai, Tohru Murayama, Hiroshi Gomyo, Kazutaka Sunami, Masanori Makita, Tatsuo Ichinohe, Noriyasu Fukushima, Isao Yoshida, Yoshihiro Yakushijin, Hiroaki Asai, Youko Suehiro, Ilseung Choi, Yasushi Takamatsu, Hidenori Sasaki, Satoshi Yamasaki, Junichi Tsukada, Hiroaki Morimoto, Shinya Kimura, Masako Yokoo, Shinichiro Yoshida, Yukiyoshi Moriuchi, Yasushi Miyazaki, Yoshitaka Imaizumi, Tatsuro Jo, Kisato Nosaka, Hiro Tatetsu, Michihiro Hidaka, Naoko Harada, Eiichi Ohtsuka, Kenji Ishitsuka, Makoto Yoshimitsu, Atae Utsunomiya, Yoshifusa Takatsuka, Satoko Morishima, Sawako Nakachi
Journal: The Lancet Haematology (2018)